To block EGF-EGFR signaling, we used the Food and Drug Administration approved EGFR-targeted therapeutics (EGFR inhibitors, EGFRi) in NPC cells, including the monoclonal antibody cetuximab (Erbitux, ERB) and a small molecule afatinib (AFA, a tyrosine kinase inhibitor), both of which can directly bind to EGFR and block the EGFR pathway. The gene discussed is EGF; the disease is nasopharyngeal carcinoma.